Latest Insider Transactions at Ayala Pharmaceuticals, Inc. (AYLA)
This section provides a real-time view of insider transactions for Ayala Pharmaceuticals, Inc. (AYLA). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Ayala Pharmaceuticals, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Ayala Pharmaceuticals, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 19
2023
|
A Moon Growth Fund Limited Partnership > 10% Shareholder |
SELL
Sale (or disposition) back to the issuer
|
Direct |
2,991,473
-100.0%
|
-
|
|
Jan 19
2023
|
Roni Mamluk President & CEO |
SELL
Sale (or disposition) back to the issuer
|
Direct |
265,345
-100.0%
|
-
|
|
Jan 19
2023
|
Gary B. Gordon Chief Medical Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
58,520
-100.0%
|
-
|
|
Jan 19
2023
|
Yossi Maimon CFO, Secretary and Treasurer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
69,872
-100.0%
|
-
|
|
Jan 19
2023
|
David Sidransky Director |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
250
-100.0%
|
-
|
|
May 16
2022
|
Roni Mamluk President & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
120,000
+31.14%
|
-
|
|
May 16
2022
|
Gary B. Gordon Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
50,000
+46.07%
|
-
|
|
May 16
2022
|
Yossi Maimon CFO, Secretary and Treasurer |
BUY
Grant, award, or other acquisition
|
Direct |
50,000
+41.71%
|
-
|
|
Feb 24
2021
|
Gary B. Gordon Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
3,000
-26.04%
|
$51,000
$17.46 P/Share
|
|
Feb 24
2021
|
Gary B. Gordon Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,000
+20.66%
|
$15,000
$5.16 P/Share
|
|
Feb 24
2021
|
Roni Mamluk President & CEO |
SELL
Open market or private sale
|
Direct |
10,800
-6.92%
|
$183,600
$17.4 P/Share
|
|
Feb 23
2021
|
Roni Mamluk President & CEO |
SELL
Open market or private sale
|
Direct |
7,126
-4.36%
|
$121,142
$17.89 P/Share
|
|
Feb 22
2021
|
Roni Mamluk President & CEO |
SELL
Open market or private sale
|
Direct |
15,200
-8.52%
|
$288,800
$19.86 P/Share
|
|
Jan 21
2021
|
Roni Mamluk President & CEO |
SELL
Open market or private sale
|
Direct |
1,406
-0.78%
|
$21,090
$15.04 P/Share
|
|
Jan 20
2021
|
Gary B. Gordon Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
3,000
-26.04%
|
$45,000
$15.03 P/Share
|
|
Jan 20
2021
|
Gary B. Gordon Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,000
+20.66%
|
$15,000
$5.16 P/Share
|
|
Jan 20
2021
|
Roni Mamluk President & CEO |
SELL
Open market or private sale
|
Direct |
19,466
-9.77%
|
$291,990
$15.03 P/Share
|
|
Jan 04
2021
|
Roni Mamluk President & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
34,080
+14.6%
|
-
|
|
Jan 04
2021
|
Yossi Maimon CFO, Secretary and Treasurer |
BUY
Grant, award, or other acquisition
|
Direct |
8,520
+30.01%
|
-
|
|
Jan 04
2021
|
Gary B. Gordon Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
8,520
+50.0%
|
-
|
|
Dec 23
2020
|
David Sidransky Director |
BUY
Open market or private purchase
|
Indirect |
4
+1.57%
|
$44
$11.56 P/Share
|
|
Sep 14
2020
|
David Sidransky Director |
BUY
Open market or private purchase
|
Indirect |
1
+0.4%
|
$10
$10.7 P/Share
|
|
Sep 11
2020
|
David Sidransky Director |
BUY
Open market or private purchase
|
Indirect |
10
+3.92%
|
$100
$10.07 P/Share
|
|
Aug 14
2020
|
David Sidransky Director |
BUY
Open market or private purchase
|
Indirect |
5
+2.08%
|
$55
$11.07 P/Share
|
|
Jul 17
2020
|
David Sidransky Director |
BUY
Open market or private purchase
|
Indirect |
4
+1.71%
|
$44
$11.86 P/Share
|
|
Jul 07
2020
|
David Sidransky Director |
BUY
Open market or private purchase
|
Indirect |
1
+0.44%
|
$9
$9.6 P/Share
|
|
May 12
2020
|
David Sidransky Director |
BUY
Open market or private purchase
|
Indirect |
25
+10.0%
|
$375
$15.02 P/Share
|
|
May 12
2020
|
Harel Insurance CO LTD > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
550,000
+10.84%
|
$8,250,000
$15.0 P/Share
|
|
May 12
2020
|
Harel Insurance CO LTD > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
519,449
+14.8%
|
-
|
|
May 08
2020
|
David Sidransky Director |
BUY
Open market or private purchase
|
Indirect |
200
+50.0%
|
$3,000
$15.27 P/Share
|